NCT03101839View on ClinicalTrials.gov

Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

January 8, 2019

Study Completion Date

January 8, 2019

Conditions
Non-Small Cell Lung CancerAdvanced Solid Tumours
Interventions
DRUG

AZD4785

KRAS Antisense Oligonucleotide

Trial Locations (5)

34232

Research Site, Sarasota

37203

Research Site, Nashville

02215

Research Site, Boston

W1G 6AD

Research Site, London

M20 4BX

Research Site, Manchester

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY